Market revenue in 2023 | USD 311.4 million |
Market revenue in 2030 | USD 382.8 million |
Growth rate | 3% (CAGR from 2023 to 2030) |
Largest segment | Antacids |
Fastest growing segment | H2 Receptor Blockers |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), Pro-kinetic agents |
Key market players worldwide | AstraZeneca PLC, Eisai Co Ltd, GSK PLC, Takeda Pharmaceutical Co Ltd, Ironwood Pharmaceuticals Inc Class A, Johnson & Johnson, Phathom Pharmaceuticals Inc Ordinary shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastroesophageal reflux disease therapeutics market will help companies and investors design strategic landscapes.
Antacids was the largest segment with a revenue share of 56.68% in 2023. Horizon Databook has segmented the UK gastroesophageal reflux disease therapeutics market based on antacids, h2 receptor blockers, proton pump inhibitors (ppis), pro-kinetic agents covering the revenue growth of each sub-segment from 2018 to 2030.
According to an article published by National Center for Biotechnology Information in 2014, in the UK, 5 out of 1,000 people suffer from GERD. Organizations such as Living with Reflux, Campaign Against Reflux Disease (CARD).
Core (Digestive Disorders Foundation) are responsible for educating people and funding research pertaining to GERD. These organizations organize weekend events, coffee mornings, and walking & cycling events to create awareness.
For instance, Living with Reflux hosts marathon once a year to raise funds for babies and children with GERD.
Horizon Databook provides a detailed overview of country-level data and insights on the UK gastroesophageal reflux disease therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into UK gastroesophageal reflux disease therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account